Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25554362 | 0.85 | STING1 (0.46) | CLK1CLK2CLK3CDK5DYRK1A | |
| SCHEMBL25025857 | 0.84 | CLK1 (0.44) | CLK1CLK2CLK3CDK5DYRK1A | |
| SCHEMBL25554263 | 0.84 | MTNR1A (0.50) | HTR2CCLK1CLK2CLK3CDK5 | |
| SCHEMBL25554355 | 0.83 | HTR2C (0.45) | HTR2CCLK1CLK2CLK3CDK5 | |
| SCHEMBL25565226 | 0.82 | CLK1 (0.41) | HTR2CCLK1CLK2CLK3CDK5 | |
| SCHEMBL6100002 | 0.79 | NR4A2 (0.61) | CLK1CLK2CLK3CDK5DYRK1A | |
| SCHEMBL31757548 | 0.79 | STING1 (0.48) | CLK1CLK2CLK3CDK5DYRK1A | |
| SCHEMBL25025855 | 0.79 | STING1 (0.48) | CLK1CLK2CLK3CDK5DYRK1A | |
| SCHEMBL25554395 | 0.77 | PIM1 (0.41) | HTR2CCLK1CLK2CDK5DYRK1A | |
| SCHEMBL25025858 | 0.77 | LMNA (0.51) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR2C 2900/4885CLK1 1338/4885CLK2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.